ALGS
NASDAQAligos Therapeutics Inc.
News · 26 weeks41+67%
2026-03-012026-08-23
Mix1790d
- Other6(35%)
- Insider6(35%)
- SEC Filings4(24%)
- Analyst1(6%)
Latest news
25 items- PRAligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in ChinaALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple ascending doses plannedStudy will allow rapid advancement into participants with chronic HBV infection in Q4 2026 SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing has been initiated in the Phase 1 study of ALG-170675, an investigational next-generation antisense oligonucleotide (ASO) being evaluated for functional cure in the treatment of chronic hepatitis B virus (HBV) i
- SECSEC Form S-8 filed by Aligos Therapeutics Inc.S-8 - Aligos Therapeutics, Inc. (0001799448) (Filer)
- SECSEC Form 10-Q filed by Aligos Therapeutics Inc.10-Q - Aligos Therapeutics, Inc. (0001799448) (Filer)
- SECAligos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Aligos Therapeutics, Inc. (0001799448) (Filer)
- PRAligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial ResultsSOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the second quarter 2026. "Our team has continued to execute on our key strategic priorities to advance our pipeline this year," stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "We strengthened our financial position through non-dilutive capital, including the $25M upfront payment related to the exclusive Greater
- PRAligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s second quarter 2026 financial results on Thursday, August 6, 2026, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ:ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep
- PRAligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV InfectionSOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment of both the HBeAg+ (Part 1a) and HBeAg- (Part 2a) participants in the Phase 2 B-SUPREME study of pevifoscorvir sodium, under development for the treatment of chronic hepatitis B virus (HBV) infection. Topline safety and efficacy data are expected to be available in late third quarter of 2027. Part 1a completed enrollment of 131 HBeAg+ participants. This represents an over enrollment pri
- PRAligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus InfectionBreakthrough Therapy Designation granted for pevifoscorvir sodium in China SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has received the upfront payment of $25M USD from the exclusive license deal of pevifoscorvir sodium in Greater China with Xiamen Amoytop Biotech Co., Ltd. (Amoytop). In addition, pevifoscorvir sodium was granted Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). Un
- INSIDERSEC Form 4 filed by Director Preston Heather4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
- INSIDERSEC Form 4 filed by Director Chavez Margarita4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
- INSIDERSEC Form 4 filed by Director Martell Bridget A4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
- INSIDERSEC Form 4 filed by Director Scopa James Paul4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
- INSIDERSEC Form 4 filed by Director Nuechterlein Carole4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
- INSIDERSEC Form 4 filed by Director Hirth Peter4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
- SECAligos Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update8-K - Aligos Therapeutics, Inc. (0001799448) (Filer)
- SECSEC Form SCHEDULE 13D filed by Aligos Therapeutics Inc.SCHEDULE 13D - Aligos Therapeutics, Inc. (0001799448) (Subject)
- ANALYSTLake Street initiated coverage on Aligos Therapeutics with a new price targetLake Street initiated coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $45.00
- PRAligos Therapeutics Presents Positive Data at the EASL Congress 2026Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoirData on the preclinical characteristics of the Aligos/Amoytop ASO program to be presented40% of HBeAg+ participants with chronic HBV infection treated with pevifoscorvir sodium at week 48 had reductions in HBsAg that would potentially allow them to qualify for ASO treatment SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from ten presentat
- ANALYSTCantor Fitzgerald initiated coverage on Aligos Therapeutics with a new price targetCantor Fitzgerald initiated coverage of Aligos Therapeutics with a rating of Overweight and set a new price target of $20.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aligos Therapeutics Inc.SCHEDULE 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
- PRAligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/. Details on the abstracts are as follows: Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) inf
- SECSEC Form 10-Q filed by Aligos Therapeutics Inc.10-Q - Aligos Therapeutics, Inc. (0001799448) (Filer)
- SECAligos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Aligos Therapeutics, Inc. (0001799448) (Filer)
- PRAligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial ResultsSOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2026. "I am pleased to continue building on our progress made so far in 2026," stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "Receiving Fast Track Designation is confirmation that an unmet medical need exists in chronic HBV infection and pevifoscorvir sodium has the potential to be superior to
- PRAligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's first quarter 2026 financial results on Thursday, May 7, 2026, after the close of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ:ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D
ALGS FAQ
7 questionsWhat does Aligos Therapeutics Inc. do?
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-Ã agonist for the treatment of non-alcoholic...Where does ALGS stock trade?
Aligos Therapeutics Inc. (ALGS) is listed on NASDAQ.What sector and industry is ALGS in?
Aligos Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Aligos Therapeutics Inc. go public?
Aligos Therapeutics Inc. (ALGS) completed its IPO in 2020.What are analysts saying about ALGS?
Aligos Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $4500.00 price target on 2026-05-28.What companies are similar to ALGS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ALGS side-by-side with any of them on Quantisnow.How can I track ALGS on Quantisnow?
Quantisnow aggregates Aligos Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALGS to receive live email and push alerts on every new disclosure.